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Abstract 
The amino acid L-arginine plays a central role in several adaptive metabolic pathways and we postulate that regulated 
L-arginine transport contributes to important physiological responses. The majority of L-arginine flux is mediated by 
transport system y+ that is encoded by at least hree genes, Cat1, Cat2 and Cat3. Cat2 encodes two distinct protein isoforms 
(CAT2/CAT2a) that differ by 10-fold in their apparent substrate affinity. Cat2 transcription is controlled by four widely 
spaced promoters. The expression of CAT2/2a transcripts was tested in skeletal muscle and macrophages following specific 
stresses or activators. Unexpectedly, CAT2a transcripts accumulated in skeletal muscle in response to surgical trauma 
(hepatectomy and splenectomy) aswell as food deprivation, although neither high affinity CAT2 nor CAT1 were detectably 
altered. Activated macrophages decreased CAT1 levels, but accumulated CAT2 and iNOS mRNA and protein with parallel 
kinetics suggesting that CAT2 mediated L-arginine transport might regulate the L-arginine:nitric oxide pathway. In 
macrophages, liver and skeletal muscle, the most distal CAT2 promoter was predominant. No change in promoter usage was 
apparent under any stress conditions tested nor was alternate splicing of the CAT2 transcript dictated by promoter usage. 
The differential regulation of the Cat genes indicates their encoded transporter proteins meet different requirements for 
cationic amino acids in the intact animal. © 1998 Elsevier Science B.V. All rights reserved. 
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NOS2; NO, nitric oxide; LPS, lipopolysaccharide; IFN-7, Inter- 
feron-y; ConA, Concanavalin A 
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Multicellular organisms regulate amino acid trans- 
port in specific organs and tissues in response to 
physiological demand [1]. The cationic amino acids 
L-lysine and L-arginine are essential and semi-essen- 
tial, respectively; hence their transport is required to 
meet cellular needs and maintain homeostasis [1,2]. 
Apart from protein synthesis, L-arginine and L-lysine 
have numerous cellular functions [3,4]. L-Arginine 
and its transport are essential for the regulated pro- 
duction of nitric oxide (NO) via the Ca2+-independ - 
ent inducible nitric oxide synthase (iNOS). Not only 
is L-arginine the sole amino group donor for NO 
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synthesis, extracellular L-arginine is essential for NO 
synthesis via iNOS [3 5]. 
The identification of cationic amino acid trans- 
porter cDNAs was an important first step in deter- 
mining the role of regulated transport in cellular re- 
sponses (reviewed in [6-9]). The three known Cat 
genes encode similar, perhaps redundant proteins, 
CAT1, CAT2 and CAT3 [10-16] and they are 
thought to comprise the functionally defined high 
affinity transport system y+ [6 9,14]. The Cat2 
gene, however, encodes two protein isoforms CAT2 
[12] and CAT2a [15] that result from mutually exclu- 
sive alternate splicing [13]. The CAT2a protein ex- 
hibits a significantly lower apparent affinity for its 
substrates and appears to comprise the low affinity 
y+ transport system found in liver [1,9,14]. The re- 
cently identified Cat3 gene is expressed exclusively in 
adult brain [16]. 
Unfortunately, it is not possible to kinetically dis- 
tinguish the three high affinity forms of the trans- 
porters and no antisera is available that reliably dis- 
tinguishes these four known CAT proteins. Hence, 
assessment of their mRNAs is the only practical 
way to determine Cat gene expression at this time. 
The CAT transcripts are expressed in distinct pat- 
terns [12]. CAT1 transcripts are constitutively and 
nearly ubiquitously expressed in normal tissues and 
cell lines, although the amounts vary widely among 
tissues [12]. The adult liver is unique in that it does 
not express CAT1 [7,10,12]; but rather, it constitu- 
tively expresses the low affinity CAT2a isoform ex- 
clusively. The constitutive xpression of CAT2/2a is 
more limited; transcripts are abundant in liver, skel- 
etal muscle and stomach as well as activated macro- 
phages and skin [12,13]. The CAT2 gene is tran- 
scribed from four distinct, widely spaced promoters 
in a T-lymphoma cell line [17]. Both Catl and Cat2 
genes are inducible in a variety of circumstances [18- 
23]. 
Dietary changes, trauma, immune challenge and 
some disease states greatly influence cationic amino 
acid uptake and metabolism [24~28]. Hence, changes 
in CAT1, CAT2 and CAT2a transcript expression 
were investigated in the liver and muscle, two organs 
involved in amino acid homeostasis. Their expression 
was also assessed in macrophages, a cell type that 
has special L-arginine requirements [3,4]. Resting 
splenocytes (largely comprised of quiescent T- and 
B-cells) express CAT1 mRNA predominately, yet 
lymphocytes exhibit extremely limited L-arginine 
and e-lysine transport [29,30]. However, following 
mitogen or antigen mediated T-cell activation, ex- 
tracellular L-arginine is required [30] and both 
CAT1 and CAT2 transcripts rapidly accumulate 
[12]. Macrophages also require extracellular L-argi- 
nine transport for NO synthesis via the inducible 
form of nitric oxide synthase (iNOS; [3,5,31]). Fur- 
thermore, macrophages increase system y+ transport 
following activation with lipopolysaccharide (LPS) 
and interferon-), (IFN-7; [32,33]) to provide these 
cells with adequate -arginine for NO synthesis. In 
this study, the expression of CAT1, CAT2 and 
CAT2a transcripts were assessed in skeletal muscle, 
liver, and smooth muscle, and from macrophages 
before and following specific activation or pathophy- 
siological stresses. CAT2 promoter utilization was 
assessed uring each of these stress or activation re- 
sponses. 
2. Materials and methods 
2.1. Surgical and dietary manipulation of mice 
Female AKR/J mice, 6 weeks of age, were ob- 
tained from Jackson Laboratories, Bar Harbor, 
ME. They were treated in accordance with the Uni- 
versity of California, San Diego and NIH guidelines 
for the humane treatment of laboratory animals. 
Surgery was performed on mice anesthetized with 
70 mg of sodium pentobarbital per kg body weight; 
either the entire spleen or 60-65% of the liver was 
removed and RNA prepared. Sham surgery was 
identical to the partial hepatectomy except the or- 
gans remained intact. After 0, 1, 2 or 7 days mice 
were killed and RNA was prepared from liver, skel- 
etal muscle (soleus and gastrocnemius), and from the 
uterus of partially hepatectomized, splenectomized or 
anesthetized control mice. Fasting studies were car- 
ried out with mice deprived of food for 24 or 48 h, 
after which they were killed and RNA prepared from 
specific organs. 
2.2. Preparation of macrophage cell line 
J774 mouse macrophages were cultured in RPMI 
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1640 medium in the presence or absence of lipopoly- 
saccharide (LPS; 100 ng/ml) and IFN-7 (10 U/ml). 
2.3. Preparation of radiolabeled probes 
Probes for Northern blot analysis were a 2.4 kb 
EcoRI fragment of CAT1 cDNA [10,15], a 2.1 kb 
MscI fragment of CAT2 cDNA [18], full-length 
iNOS cDNA (gift from Dr. Hume, [35]), a 0.7 
PstlIBamHI fragment from cyclophilin cDNA and 
a 0.2 kb AvaI fragment from 18S ribosomal cDNA 
(ATCC). Isolated cDNA fragments were labeled with 
[32p]dCTP by random priming (Amersham) and la- 
beled DNA purified on a NACS-52 column (Gibco 
BRL). Oligonucleotides (22 met) encoding CAT1, 
CAT2, and CAT2a [17], or iNOS (5'-GCAG- 
CGGCTCCATGACTCC-3') were 5'-end labeled 
with [7-32p]ATP. 
2.4. RNA preparation and analysis 
Preparation of total RNA from cultured macro- 
phages, splenocytes or tissues and Northern blot 
analysis (10 gg/lane) used standard methods as pre- 
viously described [18]. The membranes were exposed 
to XOMAT film (Kodak) within the linear range of 
detection. Stripping blots and sequentially probing 
with either 18S ribosomal cDNA assessed the 
amount of RNA loaded and transferred. Autoradio- 
graphs of Northern blots were quantitated by laser 
densitometry. 
2.5. CAT2/2a reverse transcription-polymerase chain 
reaction (RT-PCR) 
Reverse transcription of total RNA (5 ~tg) from 
the mouse cell lines SL12.4 (T-lymphoma) and J774 
(macrophage); mouse liver and skeletal and smooth 
muscle tissues was used to detect CAT2 promoter 
usage according to methods previously reported 
[17] and summarized here. The CAT2 and CAT2a 
isoforms were discriminated by priming the RT re- 
action with 5'-CGCGAATTCCGACTGTCGTGT- 
GGGCAG-Y (1453-1470 nt) located in a region 3' 
of the alternately spliced exons. The cDNA product 
was amplified using nested primers located within the 
transcribed region and flanked the alternately spliced 
region: 5'-TATCCAGACTTCTTTGCCGTGTGC_ 
3' (489-513 nt) and 5'-GTAGGCTGAAACCCTG- 
TCCTTGC-Y (1406-1429 nt). The PCR products 
were authenticated using CAT2 and CAT2a specific 
5'-end labeled oligonucleotides, CAT2: 5'-TCC- 
CAATGCCTCGTGTAATCTA-Y (1071-1093 nt); 
CAT2a: 5'-TGCAGTCATCGTGGCAGCAACG-3' 
(1159-11810 nt). The details of this assay are con- 
tained in [17]. 
2.6. Western blotting 
J774 total cell lysates were prepared by adding 
1.0 ml RIPA buffer (1% deoxycholate, 1% Triton 
X-100, 0.1% SDS, 150 mM NaC1, 2 mM MgC12, 
10 mM Tris-HC1, pH 7.2, 2 lag/ml aprotinin, 1 ~tg/ 
ml pepstatin A, 0.5 ktg/ml leupeptin) per 10 cm dish 
[34]. The 12 K supernatant was used for analysis 
following protein determination by Lowry assay 
(Bio-Rad, DC protein assay). Total cell lysates (200 
p.g/lane) were denatured with 6 molar urea and sep- 
arated by 10% SDS-PAGE. The proteins were elec- 
trophoretically transferred to supported nitrocellu- 
lose (Trans-blot, Bio-Rad). The membranes were 
blocked for 2 h (5% milk/PBS/0.1% Tween-20/0.5 M
NaC1), treated with anti-CAT2 antisera (1.0 ktg/ml) 
for 1 h with or without treating with glutathione 
S-transferase (GST) or CAT2-carboxyl terminus- 
GST fusion (pGEX-3X, Pharmacia) proteins 
(2.5 ~g/ml in 4 ml), and secondary goat-anti-rabbit 
IgG (1:5000, Bio-Rad) for 1 h. The proteins were 
detected by chemiluminescence (R naissance, NEN 
Life Science Products), and the autoradiographs 
were quantified by scanning densitometry (Bio- 
Rad). Anti-CAT2 antisera was generated by injecting 
rabbits with CAT2-GST fusion proteins encoding the 
carboxyl-terminal 70amino acids, and the IgG frac- 
tion was enriched using protein A column and am- 
monium sulfate fractionation. Membranes were 
treated at room temperature for all manipulations, 
and the anti-sera incubations contained blocking 
buffer. 
2.7. Data analysis 
Non-saturated autoradiograms were quantitated 
following RNA hybridization by densitometer scan- 
ning or Phosphoimager analysis. The absorbency ra- 
tios of hybridization signals from CAT and control 
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probes were calculated and the values were compared 
by the two-sample, two-tailed Student's t-test, using 
the INSTAT program and one way ANOVA fol- 
lowed by Duncan's test using the Number Cruncher 
Statistical System. Both tests detected the same level 
of significance. 
3. Results 
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3.1. CAT2 and CA T2a tissue distribution 
Prior to the identification of the CAT2a isoform 
[15], we reported CAT2 transcript expression in a 
variety of cell lines, tissues and organs [12,18,36]. 
To determine which CAT2 isoform is expressed in 
several organs under steady-state conditions, RNA 
samples were analyzed by RT-PCR (Fig. 1). The 
low affinity CAT2a isoform is expressed in skeletal 
muscle and liver, tissues with low amounts of the 
high affinity CAT1 [12] or CAT2 (Fig. 1A) isoforms. 
CAT2a mRNA is also predominant in skin. Recip- 
rocal expression of the high and low affinity trans- 
porters is reasonable if they play different roles in the 
import or export of their substrates. CAT1 tran- 
scripts are present in all the tissues shown in Fig. 1 
except liver [12]. 
3.2. CAT mRNA expression in unactivated and 
activated macrophages 
Macrophage activation by cytokines and LPS re- 
sults in the induction of iNOS mRNA and protein 
together with a coordinate increase in L-arginine 
transport via system y+ [14,32,33]. Activated macro- 
phages produce large amounts of NO for a sustained 
period; a response that forms part of their immuno- 
logical defense function [3-5]. iNOS mediated NO 
synthesis requires the transport of extracellular L-ar- 
ginine (e.g. [31,37]). To determine which transporters 
contribute to transport system y+ mediated L-argi- 
nine uptake, J774 macrophage cells were activated 
with LPS and IFN-y. Northern analysis (Fig. 2A) 
shows that CAT1 is expressed in unactivated cells 
and message l vels do not increase during activation, 
but instead, they actually decrease by 24 h following 
activation. In contrast, CAT2 and iNOS mRNAs 
increase in parallel from undetectable l vels in unsti- 
CAT2a "Low Affinity" 
Fig. 1. CAT expression i  normal mouse tissues. The two iso- 
forms of CAT2 were distinguished in the 15 indicated mouse 
tissues by RT-PCR; CAT1 RNA expression i these tissues 
was previously reported [12]. The reverse transcribed cDNA 
was amplified using common CAT2/2a primers flanking the 
unique alternate spliced region and distinguished by probing 
Southern blots of the amplified products with CAT2 and 
CAT2a specific oligonucleotides as described in Section 2. 
mulated cells to substantial amounts by 3 and 6 h. 
Only the high affinity CAT2, but not the low affinity 
CAT2a transcript was detected (Fig. 2B) using RT- 
PCR. This finding is concordant with reported trans- 
port studies and our own work that demonstrates 
high affinity L-arginine transport is increased uring 
activation ([32,33], Kakuda and MacLeod, unpub- 
lished). CAT2 protein is also induced from undetect- 
able levels in unactivated cells to abundant expres- 
sion in LPS/IFN-y activated cells (Fig. 2C). From 
this data, it appears that CAT2 is responsible for 
the increase in system y+ transport induced in acti- 
vated macrophages. We postulate that CAT2 medi- 
ated transport is required to supply iNOS with its 
essential substrate, L-arginine. We tested the utiliza- 
tion of alternate CAT2 promoters during macro- 
phage activation. Like splenocytes [17] only the 
most distal promoter is used (data not shown). 
3.3. CAT mRNA expression in the liver 
Normal adult liver expresses exclusively CAT2a 
transcripts although both established hepatoma cell 
lines and freshly explanted hepatocytes accumulate 
CAT1 mRNA [12,38]. It is not clear whether Cat1 
gene expression in cultured normal and neoplastic 
hepatocytes i  triggered by active cell proliferation 
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Fig. 2. Coordinate induction of CAT2 and iNOS in activated J774 macrophages. (A) Northern analysis of CAT and iNOS expression 
from untreated J774 macrophage cells (0 h), or following the addition of LPS and IFN-7 for 3, 6, and 24 h as indicated. Blots were 
probed with CAT1, CAT2/2a, iNOS and 18S cDNA probes. (B) RT-PCR analysis of CAT and iNOS expression in activated J774 
macrophage RNA. (C) Western blot of cell lysates from J774 macrophage cells unactivated or activated for 24 h and probed with 
anti-CAT2 antisera as described in Section 2. Arrowhead indicates the CAT2 specific reactivity that migrated with an estimated mass 
of 92 kDa based on molecular mass markers (not shown). 
or is a peculiar response of hepatocytes growing in 
monolayer culture [39]. To address this question, the 
expression of both genes was examined uring hepa- 
tocyte replication in vivo following surgical ablation 
of 60-70% of the liver. The remaining hepatocytes 
undergo DNA synthesis and mitosis 2448 h after 
surgery [40]. We assessed the expression of CAT2 
and CAT2a mRNA in liver following partial hepa- 
tectomy and found no detectable change in expres- 
sion of either mRNA 24 or 48 h or 7 days following 
surgery, sham surgery or fasting (Fig. 3A). In all 
conditions tested only the CAT2a transcript was ex- 
pressed (Fig. 3B). Furthermore, there was no detect- 
able change in CAT2 promoter usage in the liver 
during the most active period of cell proliferation 
(Fig. 3C.). From these data we conclude that 
CAT2a message accumulation is not changed in liver 
cells during active mitosis following partial hepatec- 
tomy; the promoter usage remains unchanged and 
there is no detectable xpression of the transcript 
encoding the high affinity isoform CAT2. 
3.4. CAT mRNA expression in skeletal and smooth 
muscles 
Surgical trauma results in the loss of substantial 
protein mass from skeletal muscle [24,25] and fasting 
induces skeletal muscle catabolism to provide circu- 
lating amino acids [41]. Since both CAT1 and CAT2 
are co-expressed in skeletal muscle [12], we tested 
whether surgical trauma or fasting altered their ex- 
pression. Northern analysis of skeletal muscle expres- 
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Fig. 3. CAT mRNA in liver following hepatectomy, sham surgery and fasting. Northern analysis (10 ~tg/lane) of CAT2/2a RNA ex- 
pression from the liver of a representative group of animals. The left panel shows data from resected liver (C) or from liver 1, 2 or 
7 days following partial hepatectomy or sham-operated animals as indicated. The middle and right panels shows CAT2/2a liver ex- 
pression 0, 1 or 2 days following splenectomy, 1 day after anesthesia alone (A), or after 1 or 2 days of fasting. RNA loading controls 
are shown at the bottom of the panel. (B) RT-PCR analysis of CAT2 and CAT2a expression in liver following hepatectomy, splenec- 
tomy, and fasting (24 h). RNA from SL12.4 T-cells served as a positive control for CAT2. (C) CAT2 promoter usage in liver follow- 
ing the indicated treatments. RNA was prepared separately from six animals in each treatment or control group; representative data 
are shown. Details are provided in the legend to Fig. 2 and in Section 2. 
sion illustrates CAT2/2a transcripts are substantially 
induced (Fig. 4A) following partial hepatectomy, 
whereas CAT1 mRNA levels remain low and unal- 
tered (not shown). The most pronounced increase, 
8.7-fold (P = 0.03), occurred 1 day after hepatectomy 
(Fig. 4A). This increase was linked to liver regener- 
ation, since it was not observed in sham-operated 
animals. Two days after hepatectomy, CAT2/2a 
mRNA had returned to control levels (not shown). 
Splenectomy also significantly induced CAT2/2a 
mRNA 3.5-fold (P = 0.001) and it decreased to base- 
line 2 days later (not shown). Finally, Fig. 4A, right 
shows fasting produced a 2.4-fold, significant in- 
crease in CAT2a mRNA (P = 0.0005). CAT1 
mRNA levels were not significantly altered by these 
treatments (not shown). Interestingly, only isoform 
CAT2a is induced in response to hepatectomy, sple- 
nectomy and fasting (Fig. 4B). Perhaps the expres- 
sion of this low affinity CAT2a isoform spares the 
muscle cell from excessive release of its L-arginine 
stores (see Section 4). Only a subtle change in pro- 
moter usage was detected in skeletal muscle follow- 
ing hepatectomy (Fig. 4C). As yet, this utilization of 
the 1D promoter is the only condition in which pro- 
moters other than 1A are utilized except in cell lines 
[17]. We can conclude, however, that promoter usage 
does not dictate the selection of splicing events that 
produce CAT2/2a isoforms since the same promoter 
is used exclusively in macrophages that exclusively 
express the high affinity CAT2 isoform and in liver 
and muscle, where only the low affinity isoform is 
expressed. In addition, Cat gene expression was as- 
sessed in the uterus, a smooth muscle. No change in 
expression of either CAT1 or CAT2 was detected 
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Fig. 4. CAT mRNA in skeletal muscle following hepatectomy, splenectomy and fasting. (A) Left side: Northern analysis (10 gg/lane) 
of skeletal muscle CAT2/2a mRNA expression 1 day following partial hepatectomy (lanes labeled 1) or the anesthesia control (A) or 
from untreated mice (0). Middle: Northern analysis of skeletal muscle CAT2/2a mRNA expression following splenectomy. Right: 
Northern analysis of skeletal muscle following 1 or 2 days of fasting all compared to 18S ribosomal RNA as a control for loading. 
Procedures are described in Section 2. (B) RT-PCR analysis of CAT2 and CAT2a isoforrn expression i  skeletal muscle following the 
indicated conditions. (C) Promoter usage in skeletal muscle following the indicated treatments as previously described [17]. The letters 
designate the distinct CAT2 promoters [17]. 
following hepatectomy, splenectomy or fasting (data 
not shown) in response to the same conditions that 
stimulated CAT2a mRNA expression in striated 
muscle. Unlike skeletal muscle, the uterus expresses 
only the CAT2 and not the CAT2a isoform. Hence, 
CAT2a induction is specific for skeletal muscle, and 
is not induced in this smooth muscle. 
4. Discussion 
Three related genes encode four proteins that re- 
semble the Na+-independent low and high affinity y+ 
transport system [10-12,16] when expressed in Xen- 
opus oocytes and thereby appear to have overlapping 
functions [13,16], However, their expression patterns 
are quite distinct; CAT1 expression is nearly ubiqui- 
tous, CAT2 has more limited expression and CAT3 
is expressed exclusively in the adult brain, (where 
both CAT1 and CAT2 are also expressed [16]). 
Catl and Cat,? genes have distinct expression pat- 
terns from one another [12]. Cat2 is expressed from 
multiple promoters [17] and encodes two mutually 
exclusive alternate splicing isoforms [8,13] that have 
substantially different transport kinetic properties 
[8,42,43]. We postulated that regulatory requirements 
might explain the apparently redundant function of 
these genes. 
Hepatic low affinity transport system y+ is likely to 
be encoded by the constitutively expressed CAT2a 
isoform [8,13,15]. Although hepatic system y+ trans- 
port activity is stimulated following glucagon admin- 
istration and requires new RNA synthesis [25], our 
data show that food deprivation, which elevates plas- 
ma glucagon, does not alter CAT2a RNA levels in 
liver. CAT1 is transiently induced 2-6 h following 
partial hepatectomy and in response to insulin, dex- 
amethasone, or L-arginine treatment [19]. Our partial 
hepatectomy studies were conducted to examine the 
effects of mitosis per se on CAT expression, hence 
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regenerating liver was examined during the time 
characterized by hepatic cellular proliferation (24- 
48 h). No change in CAT1 or CAT2/2a mRNA 
was observed uring this time period even though 
the regenerating liver is synthesizing L-lysine- and 
L-arginine-rich istones and shows no decrease in 
free intracellular e-lysine and e-arginine concentra- 
tions [44]. These data suggest here is increased cat- 
ionic amino acid transport, perhaps mediated by the 
transient induction of CAT1 [19], although the ex- 
pression levels of CAT2, CAT2a and CAT1 under 
these conditions have yet to be ascertained. 
Skeletal muscle plays a unique role in amino acid 
homeostasis, ince its protein mass serves as the ma- 
jor source of plasma amino acids in several physio- 
logical conditions. CAT2a expression predominates 
in skeletal muscle and is induced in response to sur- 
gical trauma and fasting. However, pathophysiolog- 
ical conditions that alter both liver and skeletal 
muscle metabolism induce CAT2a mRNA levels in 
skeletal muscle, but not in the liver. The apparent Km 
of skeletal muscle y+ transport is around 2 mM [28], 
which is similar to the low affinity CAT2a isoform 
[8,15]. CAT2a induction could increase cationic ami- 
no acid release into the systemic irculation during 
fasting and surgical trauma when there is a net ami- 
no acid export of lysine from skeletal muscle [45]. 
Because the low affinity isoform would require a 
high intracellular concentration of free amino acid 
to stimulate export of lysine, it might spare the 
muscle from excess loss of their cationic amino acid 
stores. Changes in unknown circulating factors after 
fasting, splenectomy and partial hepatectomy might 
account for the quantitative difference in skeletal 
muscle CAT2 induction in response to such stress. 
However, the fact that promoter 1A utilization re- 
mains predominant seems puzzling since each CAT2 
promoter contains distinct potential transcription 
factor binding motifs that indicate a range of regu- 
latory factors could influence Cat2 gene expression. 
Nevertheless, our data show that the CAT2 pro- 
moter 1A is predominant in all tissues and cell lines 
examined regardless of: (1) the stresses applied; (2) 
the tissue examined; or (3) which alternate splicing 
event occurs during processing of the transcript. Fur- 
thermore, our data show that promoter usage does 
not dictate the alternate splicing events that give rise 
to the two protein isoforms, CAT2/2a since both 
liver (that expresses CAT2a exclusively) and macro- 
phages (that express CAT2 exclusively) both utilize 
only promoter IA. 
The regulated expression of Cat genes has been 
investigated in several distinct cell types [18-23]. 
These investigations identified regulated expression 
of CAT2 and cationic amino acid transport in re- 
sponse to a variety of physiological stimuli, such as 
cytokines, bacterial products (LPS) and hormones 
[19,21--23]. Similar to our results with activated mac- 
rophages, CAT2 (but not CAT2a or CAT1) and 
iNOS were co-induced in astrocytes and vascular 
smooth muscle cells [21,20] when the demand for 
cellular arginine sharply rises. 
With regard to possible redundancy of the Cat 
gene family of transporters, Perkins et al. found 
that ablation of Catl is lethal following birth, 
although embryonic development is almost com- 
pletely normal in Catl /-  knockout embryos [46]. 
Therefore, Cat2, Cat3 or other genes have the ca- 
pacity to substitute for the absence of Catl gene 
function during embryonic development, but cannot 
sustain viability for more than 6 h following birth 
[46,47]. When the Cat2 and Cat3 genes are ablated, 
it will be possible to determine whether these genes 
are required for normal development or the mainte- 
nance of cationic amino acid homeostasis. Further- 
more, if they are viable, such knockout animals will 
make it possible to determine whether Cat regulatory 
responses are altered by mutational loss of one or 
more Cat genes. 
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